A clinical-stage biotechnology company in immunotherapy

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more

23/06/2022

OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting

Download

To receive OSE Immunotherapeutics’ latest news